Navigation Links
ReBuilder Medical Technologies, Inc. Announces Revolutionary Electronic 'Zapper' Said to Destroy Molluscum Contagiosum Pathogen

CHARLES TOWN, W.Va., March 20 /PRNewswire/ -- ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM), developers of state of the art electronic devices for diabetic peripheral neuropathy, Molluscum Contagiosum, and MRSA; today announced that it has not only completed its development cycle of its highly secreted electronic treatment system for Molluscum Contagiosum, but has released it for sale on

(Logo: )

"We have been successfully treating Molluscum with our proprietary nano-silver ointment for the past 4 years." says David B. Phillips, Ph.D., President of RBRM. "Although it has been the only painless treatment, it can take from 3 weeks to 3 months to achieve complete remission; now patients can begin to see success in as little as 3 days."

"We have priced the complete system at $299 so emotionally distraught parents can afford immediate relief." says Daena Carter, CFO of RBRM.

The system was recently featured on TV and can be viewed on the company's home page:

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.

SOURCE ReBuilder Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Announces 2007 Sales Nearly Doubled Sales in 2006
2. ReBuilder Medical Technologies, Inc. Expands R&D of New Products
3. ReBuilder Medical Technologies, Inc. Announces Televised Broadcast
4. ReBuilder Medical Technologies, Inc. 4th Quarter Sales Increase 100% Exceeding Projections
5. ReBuilder Medical Technologies, Inc. Reports Doubled Profits for October
6. ReBuilder Medical Technologies, Inc. Announces Record Sales Month
7. ReBuilder Medical Technologies, Inc. Celebrates Five Years and 50,000th Shipment
8. ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support
9. ReBuilder Medical Technologies, Inc. Increases Manufacturing Space to Meet Demand
10. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
11. ReBuilder Medical Technologies, Inc. Announces Agreement with Internet Marketer Helio Health; Anticipates 12% Additional Profit
Post Your Comments:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
Breaking Medicine Technology: